Why is Medicamen Biotech Ltd ?
1
Company has a low Debt to Equity ratio (avg) at 0.03 times
2
Poor long term growth as Operating profit has grown by an annual rate -2.86% of over the last 5 years
3
Positive results in Sep 26
- NET SALES(9M) At Rs 163.38 cr has Grown at 36.35%
- PAT(9M) At Rs 9.39 cr has Grown at 29.70%
- PBDIT(Q) Highest at Rs 8.68 cr.
4
Stock is technically in a Mildly Bullish range
- The technical trend has improved from Sideways on 06-Nov-26 and has generated 4.12% returns since then
- The stocks Bollinger Band and KST technical factors are also Bullish
5
With ROE of 4.1, it has a Fair valuation with a 1.4 Price to Book Value
- The stock is trading at a discount compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of -29.16%, its profits have risen by 8.1% ; the PEG ratio of the company is 8.1
6
Consistent Underperformance against the benchmark over the last 3 years
- Along with generating -29.16% returns in the last 1 year, the stock has also underperformed BSE500 in each of the last 3 annual periods
How much should you hold?
- Overall Portfolio exposure to Medicamen Biotec should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Medicamen Biotec for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Medicamen Biotec
-29.16%
-0.53
54.66%
Sensex
-2.0%
-0.13
14.98%
Quality key factors
Factor
Value
Sales Growth (5y)
12.99%
EBIT Growth (5y)
-2.86%
EBIT to Interest (avg)
4.19
Debt to EBITDA (avg)
1.62
Net Debt to Equity (avg)
0.02
Sales to Capital Employed (avg)
0.66
Tax Ratio
18.98%
Dividend Payout Ratio
14.07%
Pledged Shares
0
Institutional Holding
4.40%
ROCE (avg)
6.39%
ROE (avg)
5.09%
Valuation Key Factors 
Factor
Value
P/E Ratio
35
Industry P/E
40
Price to Book Value
1.43
EV to EBIT
26.22
EV to EBITDA
17.93
EV to Capital Employed
1.42
EV to Sales
1.95
PEG Ratio
8.14
Dividend Yield
0.34%
ROCE (Latest)
5.43%
ROE (Latest)
4.11%
Loading Valuation Snapshot...
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
No Trend
Technical Movement
11What is working for the Company
NET SALES(9M)
At Rs 163.38 cr has Grown at 36.35%
PAT(9M)
At Rs 9.39 cr has Grown at 29.70%
PBDIT(Q)
Highest at Rs 8.68 cr.
OPERATING PROFIT TO NET SALES(Q)
Highest at 15.83%
PBT LESS OI(Q)
Highest at Rs 5.12 cr.
-4What is not working for the Company
OPERATING CF(Y)
Lowest at Rs -33.17 Cr
Loading Valuation Snapshot...
Here's what is working for Medicamen Biotec
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 5.12 cr has Grown at 121.65%
Year on Year (YoY)MOJO Watch
Near term PBT trend is very positive
PBT less Other Income (Rs Cr)
Net Sales - Nine Monthly
At Rs 163.38 cr has Grown at 36.35%
Year on Year (YoY)MOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Profit After Tax (PAT) - Nine Monthly
At Rs 9.39 cr has Grown at 29.70%
Year on Year (YoY)MOJO Watch
Near term PAT trend is positive
PAT (Rs Cr)
Operating Profit (PBDIT) - Quarterly
Highest at Rs 8.68 cr.
in the last five quartersMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (Rs Cr)
Operating Profit Margin - Quarterly
Highest at 15.83%
in the last five quartersMOJO Watch
Company's efficiency has improved
Operating Profit to Sales
Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 5.12 cr.
in the last five quartersMOJO Watch
Near term PBT trend is positive
PBT less Other Income (Rs Cr)
Here's what is not working for Medicamen Biotec
Operating Cash Flow - Annually
Lowest at Rs -33.17 Cr and Fallen
each year in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (Rs Cr)